Klaus Charissé
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques, DNA and Nucleic Acid Chemistry, RNA modifications and cancer, MicroRNA in disease regulation
Most-Cited Works
- → Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs(2004)2,171 cited
- → Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery(2012)1,163 cited
- → Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing(2014)1,048 cited
- → Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown(2015)637 cited
- → Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates(2008)636 cited
- → Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics(2013)602 cited
- → In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight(2014)568 cited
- → FGF Regulates TGF-β Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression(2012)296 cited
- → An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia(2015)291 cited
- → Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates(2017)259 cited